爱硒健康网丨广东爱硒健康管理有限公司官网

2022 ASCO中国之声|临床科学论坛、口头报告、壁报讨论部分共34项中国研究入选

一年一度的全球肿瘤界盛会-美国临床肿瘤学会(ASCO)年会将于当地时间6月3日-6月7日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议,致力于癌症的预防、治疗和改善患者管理,以展示肿瘤的基础研究和临床最新研究为特点,讨论当前国际先进的治疗方法。

随着中国临床研究在肿瘤领域的快速成长,中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上,中国研究入选Clinical Science Symposium 3项;Oral Abstract Session 15项;Poster Discussion Session 17项。期待中国专家在ASCO年会上展现风采!

临床科学论坛

胃肠道肿瘤——胃食管癌、胰腺癌、肝胆癌

01

摘要号: LBA4011

标题:Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

报告人:秦叔逵

单位:南京金陵医院

特别会议

02

摘要号:106

标题:A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).

报告人:王静

单位:湖南省肿瘤医院

血液恶性肿瘤

03

摘要号:7008

标题:Autologous CD19-directed CAR T cells produced by novel PrimeCAR manufacture platform exhibit safety, efficacy, and long persistence profiles in relapsed/refractory B-lineage acute leukemia (r/r B-ALL).

报告人:黎诗琦

单位:中国人民解放军联勤保障部队第九二〇医院

口头报告

治疗发展——分子靶向药物和肿瘤生物学

01

摘要号:3000

标题:A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors.

报告人:吴令英

单位:中国医学科学院肿瘤医院

胃肠道肿瘤——结直肠癌和肛门癌

02

摘要号:3500

标题:Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial.

报告人:胡华斌

单位:中山大学附属第六医院

泌尿生殖系统——肾癌和膀胱癌

03

摘要号:4507

标题:TRUCE-02: An open label, single-arm, phase II study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma.

报告人:王海涛

单位:天津医科大学第二医院

泌尿生殖系统——前列腺癌、睾丸癌和阴茎癌

04

摘要号:5005

标题:A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

报告人:叶定伟

单位:复旦大学附属肿瘤医院

头颈部肿瘤

05

摘要号:6000

标题:Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial.

报告人:马骏

单位:中山大学肿瘤防治中心

06

摘要号:6001

标题:Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.

报告人:孙艳

单位:北京大学肿瘤医院

07

摘要号:6002

标题:Reduced-dose radiotherapy for pretreatment EBV DNA selected low-risk stage III nasopharyngeal carcinoma: A single-arm, phase II trial.

报告人:麦海强

单位:中山大学肿瘤防治中心

血液恶性肿瘤

08

摘要号:7501

标题:GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL).

报告人:黄慧强

单位:中山大学肿瘤防治中心

09

摘要号:8004

标题:Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).

报告人:黄河

单位:浙江大学医学院附属第一医院

10

摘要号:8005

标题:Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

报告人:杜鹃

单位:上海长征医院

肺癌

11

摘要号:8500

标题:Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.

报告人:邱福铭

单位:浙江大学医学院附属第二医院

12

摘要号:8505

标题:Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

报告人:程颖

单位:吉林省肿瘤医院

黑色素瘤/皮肤癌

13

摘要号:9508

标题:A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM).

报告人:斯璐

单位:北京大学肿瘤医院

肉瘤

14

摘要号:11502

标题:Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A*02:01 patients with advanced soft tissue sarcoma.

报告人:张星

单位:中山大学肿瘤防治中心

症状和生存

15

摘要号:12001

标题:Correlation of psychological distress with quality of life and efficacy of immune checkpoint inhibitors in patients with newly diagnosed stage IIIB-IV NSCLC.

报告人:吴芳

单位:中南大学湘雅二医院

壁报讨论

治疗发展——免疫治疗

01

摘要号:2512

标题:Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF‑β, in patients with advanced tumors.

报告人:郭晔

单位:同济大学附属东方医院

治疗发展——分子靶向药物和肿瘤生物学

02

摘要号:3011

标题:A multicenter, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.

报告人:胡晓洁

单位:上海交通大学医学院附属第九人民医院

胃肠道肿瘤——结直肠癌和肛门癌

03

摘要号:3515

标题:Primary surgery followed by selective radiochemotherapy versus conventional preoperative radiochemotherapy for patients with locally advanced rectal cancer with MRI-negative circumferential margin (PSSR): A multicenter, randomized, open-label, noninferiority, phase 3 trial.

报告人:丁克峰

单位:浙江大学医学院附属第二医院

04

摘要号:3516

标题:Short-term outcomes of laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): A multicenter, randomized, controlled trial.

报告人:池畔

单位:福建医科大学附属协和医院

胃肠道肿瘤——胃食管癌、胰腺癌、肝胆癌

05

摘要号: 4013

标题:Postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX to improve outcomes of patients with hepatocellular carcinoma with microvascular invasion: A prospective multicenter, phase 3, randomized, controlled clinical trial.

报告人:李少华

单位:中山大学肿瘤防治中心

06

摘要号:4016

标题:Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).

报告人:孟雪

单位:山东省肿瘤医院

07

摘要号:4017

标题:Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).

报告人:齐长松

单位:北京大学肿瘤医院

泌尿生殖系统——肾癌和膀胱癌

08

摘要号:4518

标题:Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma.

报告人:盛锡楠

单位:北京大学肿瘤医院

09

摘要号:4519

标题:A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.

报告人:Huayan Xu

单位:北京大学肿瘤医院

10

摘要号:4520

标题:RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.

报告人:盛锡楠

单位:北京大学肿瘤医院

头颈部肿瘤

11

摘要号:6012

标题:Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage TanyN3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.

报告人:Hu Liang

单位:中山大学肿瘤防治中心

血液恶性肿瘤

12

摘要号:7513

标题:Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.

报告人:桂琳

单位:中国医学科学院肿瘤医院

肺癌

13

摘要号:8516

标题:Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer: An objective performance trial.

报告人:马淑香

单位:河南省肿瘤医院

黑色素瘤/皮肤癌

14

摘要号:9512

标题:Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.

报告人:崔传亮

单位:北京大学肿瘤医院

肉瘤

15

摘要号:11513

标题:Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).

报告人:邱海波

单位:中山大学肿瘤防治中心

16

摘要号:11519

标题:Phase I study of pegylated liposomal doxorubicin in combination with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory sarcoma and other malignant solid tumors.

报告人:路素英

单位:中山大学肿瘤防治中心

备注:排名不分先后,按照摘要号进行

加硒教授微信:623296388,送食疗电子书,任选一本

分享到:更多 ()

评论 抢沙发

  • 昵称 (必填)
  • 邮箱 (必填)
  • 网址